We also evaluated the effects of these compounds on the growthand viability of four cancer cell lines in vitro.Two of the cell lines (NUGC-3, gastric cancer cell line with a TP53 Y220C mutation and T3M-4, pancreatic carcinoma cellline) have the TP53 Y220C mutation leading to thep53 Y220C mutant protein; SJSA-1 is a p53 WT cell line, and NUGC-3-KOis an isogenic p53 knockout cell line.11 After incubating the cells with the compounds for five days, cellviability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay. The gene discussed is TP53; the disease is exocrine pancreatic carcinoma.